Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

PTH decreased cell apoptosis in a Flt-3L expanded population. by Flavia Q. Pirih (360515)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

Choroidal Neovascularization Is Inhibited in Splenic-Denervated or Splenectomized Mice with a Concomitant Decrease in Intraocular Macrophage by Xue Tan (2994324)

Decreased Fhl1b activity augments induction of pancreatic endocrine cells. by Jin Xu (31283)

Knockdown of p65 in A549 cells results in a decreased infection rate. by Janine J. Wilden (8849948)

Decreasing phagocytosis did not block NRF2 activation in <i>Lgy</i> infection. by Marta Reverte (10450927)

Decreased Tbx2 expression in the AV myocardium of <i>Ezh2</i> mutant mice. by Li Chen (5749)

Deletion of <i>ERG251-A</i> but not <i>ERG251-B</i> leads to decreased filamentation. by Xin Zhou (54275)

Subjects:

a-c: Bone marrow (BM) EPO receptor (EPO-R) decreases in uremic anemia rats. by Daniel Landau (440830)

“…<p>BM EPO-R protein (depicted as percentage of actin-corrected concentration) is unchanged in 7 day-bled rats Vs controls (Fig. 4a). Contrary to that BM EPO-R protein decreases in uremic (4 weeks after 5/6 nephrectomy) rats (Fig. 4b). …”